Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 433,722 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.07, for a total value of $4,801,302.54. Following the transaction, the chief operating officer now directly owns 1,243,475 shares of the company's stock, valued at approximately $13,765,268.25. The trade was a 25.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Eric Venker also recently made the following trade(s):
- On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The shares were sold at an average price of $11.22, for a total value of $6,353,639.16.
- On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00.
- On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00.
- On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96.
- On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32.
Roivant Sciences Stock Up 0.3%
NASDAQ:ROIV traded up $0.03 during trading hours on Friday, reaching $11.23. The company had a trading volume of 4,927,975 shares, compared to its average volume of 5,562,342. The business's 50-day simple moving average is $10.61 and its two-hundred day simple moving average is $11.02. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of -74.86 and a beta of 1.16. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. The firm had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Parallel Advisors LLC grew its holdings in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after buying an additional 1,108 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Roivant Sciences in the 4th quarter worth $39,000. UMB Bank n.a. grew its stake in shares of Roivant Sciences by 112.7% in the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after acquiring an additional 2,195 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in shares of Roivant Sciences by 59.3% in the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after purchasing an additional 1,905 shares during the last quarter. Institutional investors own 64.76% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, May 28th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.
Get Our Latest Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
